

Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations

*Emmanuel Ifeanyi Obeagu¹, Arinze Favour Anyiam² and Getrude Uzoma Obeagu³

¹Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

²Department of Medical Laboratory Science, School of Basic Medical and Health Sciences, Igbinedion University, Okada, Edo State, Nigeria.

School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Anemia represents a prevalent and multifaceted complication in individuals living with Human Immunodeficiency Virus (HIV), necessitating a comprehensive understanding of its mechanisms and tailored management strategies. This review explores the clinical considerations and innovative approaches in the management of anemia in the context of HIV, with a specific focus on blood transfusions. From unraveling the intricate interplay between HIV and anemia to evaluating the risks and benefits of blood transfusions, this article synthesizes current knowledge and outlines emerging strategies for more effective anemia management. The review addresses diagnostic challenges, clinical guidelines, and the impact of anemia on patient quality of life. Furthermore, it delves into innovative approaches, including erythropoiesis-stimulating agents and iron supplementation, highlighting their potential to optimize erythropoiesis in the context of HIV. The challenges associated with blood transfusions, such as transfusion-transmitted infections and immunomodulatory effects, are explored within the broader context of patient-centered care. The review concludes by outlining future directions and research needs, envisioning a path toward improved outcomes and enhanced quality of life for individuals living with HIV and anemia.

Keywords: *HIV, anemia, blood transfusions, hemoglobin levels, iron supplementation, erythropoiesis-stimulating agents, clinical guidelines, innovation*

Introduction

Anemia stands as a pervasive hematologic complication in the intricate landscape of Human Immunodeficiency Virus (HIV) infection, contributing to a multitude of clinical challenges and impacting the overall well-being of affected individuals. The interplay between HIV and anemia

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

is complex, involving viral-mediated effects on hematopoiesis, opportunistic infections, and the side effects of antiretroviral therapies. Among the diverse strategies for managing anemia in the context of HIV, blood transfusions emerge as a critical intervention for addressing severe cases and improving immediate hemoglobin levels.¹⁻¹⁵ This paper aims to set the stage for a comprehensive exploration of the clinical considerations and innovative approaches in managing anemia in individuals living with HIV, with a specific focus on the role of blood transfusions. The prevalence and significance of anemia in the HIV population underscore the importance of tailored interventions that consider the multifactorial nature of its etiology. Anemia is a prevalent comorbidity in individuals with HIV, affecting a substantial proportion of the population. Its impact extends beyond hematologic indices, influencing the progression of HIV disease, patient quality of life, and overall clinical outcomes. Understanding the epidemiology and consequences of anemia in the context of HIV is fundamental for developing effective management strategies.¹⁶⁻²⁵

The pathophysiology of anemia in HIV involves intricate interactions between the virus and the hematopoietic system. Direct effects on erythropoiesis, opportunistic infections targeting red blood cell production, and adverse effects of antiretroviral therapies contribute to the multifactorial etiology of anemia. A thorough exploration of these mechanisms is essential for guiding targeted interventions.²⁶⁻³⁶ Diagnosing and managing anemia in individuals with HIV requires a nuanced approach. Blood transfusions represent a cornerstone in the management of severe anemia in individuals with HIV. Beyond traditional interventions, innovative approaches play a pivotal role in optimizing anemia management in HIV.³⁷⁻⁴⁶

HIV-Related Mechanisms of Anemia

The coexistence of Human Immunodeficiency Virus (HIV) infection and anemia unveils a complex interplay involving intricate mechanisms that impact hematopoiesis at various levels. Understanding these HIV-related mechanisms of anemia is essential for developing targeted and effective management strategies. HIV can directly influence erythropoiesis through several mechanisms. The virus may infect and damage hematopoietic progenitor cells, impairing their ability to generate red blood cells. Additionally, the production of pro-inflammatory cytokines in response to HIV infection contributes to the inhibition of erythropoiesis, creating a microenvironment unfavorable for optimal red blood cell production. Chronic inflammation is a hallmark of HIV infection, driven by elevated levels of pro-inflammatory cytokines. This inflammatory milieu disrupts the delicate balance of cytokine regulation, affecting the erythropoietin signaling pathway and leading to impaired production of red blood cells. Interleukin-1 β , tumor necrosis factor- α , and interferon- γ play pivotal roles in mediating these inflammatory responses.⁴⁷⁻⁶⁰

Opportunistic infections associated with advanced HIV disease, such as *Mycobacterium avium* complex and cytomegalovirus, can directly impact hematopoiesis. These infections may invade the bone marrow, disrupt hematopoietic stem cell function, or induce cytokine production that negatively affects erythropoiesis. The cumulative effect of opportunistic infections further

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

exacerbates anemia in individuals with HIV. HIV-associated anemia is often characterized by alterations in iron metabolism. The virus can modulate hepcidin, a key regulator of iron homeostasis, leading to increased sequestration of iron in macrophages and reduced iron availability for erythropoiesis. This dysregulation contributes to the development of anemia, particularly in the setting of chronic inflammation. HIV-induced bone marrow suppression involves a complex cascade of events, including direct viral effects on hematopoietic progenitor cells and alterations in the bone marrow microenvironment. The virus may induce changes in stromal cells and the extracellular matrix, further compromising the supportive niche required for normal erythropoiesis. While antiretroviral therapy (ART) has revolutionized the management of HIV, certain drug classes, such as zidovudine, can contribute to anemia. Zidovudine-induced mitochondrial toxicity in erythroid precursors impairs their function and can lead to a macrocytic anemia. Balancing the benefits of ART with potential hematologic complications is crucial in the overall management of HIV-related anemia.⁶¹⁻⁷⁰

Clinical Considerations in Anemia Management

Effectively managing anemia in individuals living with Human Immunodeficiency Virus (HIV) demands a comprehensive understanding of the clinical nuances associated with this dual burden. Accurate assessment of hemoglobin levels serves as the cornerstone of anemia diagnosis and management. Regular monitoring, especially in individuals with HIV, helps detect anemia early, enabling timely intervention. Diagnosis should consider the potential influence of comorbidities, medications, and HIV-related factors on hemoglobin levels. Anemia in individuals with HIV often results from multifactorial causes. Identifying and addressing contributory factors, including opportunistic infections, nutritional deficiencies, and adverse effects of antiretroviral therapy, are paramount. A comprehensive assessment helps tailor interventions to the specific needs of each patient. Beyond hemoglobin levels, a thorough hematologic evaluation, including reticulocyte count, mean corpuscular volume (MCV), and peripheral blood smear examination, provides insights into the underlying etiology of anemia. These parameters aid in distinguishing between different types of anemia and guide targeted interventions.⁷¹⁻⁷³

Anemia management in individuals with HIV necessitates individualized treatment plans. Tailoring interventions based on the underlying cause, severity of anemia, and the patient's overall health status enhances the efficacy of treatment.⁷⁴ This approach accounts for the heterogeneity of anemia etiology in the HIV population. Antiretroviral therapy (ART) is a cornerstone in HIV management; however, certain drug classes can contribute to anemia. Understanding the potential hematologic side effects of ART, such as zidovudine-induced macrocytic anemia, enables clinicians to make informed decisions regarding treatment regimens. Opportunistic infections common in advanced HIV disease, such as *Mycobacterium avium* complex and cytomegalovirus, can exacerbate anemia. Effective management of these infections is integral to anemia control. Coordination between infectious disease specialists and hematologists is essential for a comprehensive approach. Anemia often has psychosocial implications, impacting the quality of life and daily functioning of individuals with HIV. Incorporating psychosocial considerations into the treatment plan, providing patient education on the importance of adherence to interventions,

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

and addressing concerns contribute to holistic anemia management. Anemia management is an ongoing process that requires regular follow-up and monitoring. Periodic assessments of hemoglobin levels, treatment efficacy, and potential side effects ensure that interventions are adjusted as needed. This proactive approach optimizes long-term outcomes.

Blood Transfusions in HIV-Associated Anemia

The management of anemia in individuals living with Human Immunodeficiency Virus (HIV) often necessitates interventions aimed at rapidly correcting low hemoglobin levels and improving overall well-being. Blood transfusions represent a crucial therapeutic modality in the arsenal against severe anemia. Blood transfusions are indicated in individuals with HIV-associated anemia when hemoglobin levels fall to critical thresholds, leading to symptoms such as fatigue, dyspnea, or compromised tissue oxygenation. The decision to transfuse is guided by the severity of anemia, the presence of symptomatic manifestations, and the underlying clinical context.⁷⁵ Determining the appropriate transfusion threshold is a critical clinical consideration. While specific thresholds may vary, especially in the setting of HIV, common criteria include hemoglobin levels below 7 to 8 g/dL for asymptomatic patients and higher thresholds for those with symptomatic anemia or underlying cardiovascular disease. Individualized assessments are paramount.

Ensuring compatibility between the donor blood and the recipient is fundamental to prevent transfusion reactions. For individuals with HIV, additional considerations may include selecting blood from donors with similar HIV strains and using leukoreduced blood products to minimize the risk of transfusion-related complications. Blood transfusions, while effective, are not without risks. Individuals with HIV may face specific challenges, including increased susceptibility to transfusion-transmitted infections. Rigorous screening measures and adherence to safety protocols are imperative to minimize these risks and ensure the overall safety of the transfusion process. The potential impact of blood transfusions on HIV disease progression remains a topic of discussion. While transfusions themselves do not accelerate HIV replication, the immunomodulatory effects of blood products and the potential introduction of immune-activating factors should be considered. The overall impact on the course of HIV infection requires ongoing research. The primary goal of blood transfusions in HIV-associated anemia is to rapidly increase hemoglobin levels and alleviate symptoms. Monitoring the efficacy of transfusions involves assessing post-transfusion hemoglobin levels, symptomatic improvement, and overall clinical response. Regular follow-up is crucial to evaluate the sustainability of transfusion benefits.⁷⁵

In certain situations, alternatives to blood transfusions may be considered. Erythropoiesis-stimulating agents (ESAs) and iron supplementation are examples of interventions that aim to stimulate endogenous red blood cell production. These alternatives should be weighed against the risks and benefits of blood transfusions in the individual clinical context. Blood transfusions should be seamlessly integrated into the broader management of individuals with HIV, including coordination with antiretroviral therapy (ART). Addressing ART-related complications, such as zidovudine-induced anemia, and optimizing HIV control contribute to overall treatment success. While blood transfusions provide immediate relief from severe anemia, a comprehensive long-

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

term management plan is essential. Identifying and addressing underlying causes, optimizing antiretroviral therapy, and considering innovative approaches, such as erythropoiesis-stimulating agents, contribute to sustained anemia control.⁷⁵

Innovations in Anemia Management

The landscape of anemia management in individuals living with Human Immunodeficiency Virus (HIV) has witnessed notable advancements, with ongoing research and innovation paving the way for more effective and targeted interventions. ESAs represent a transformative innovation in the management of anemia, stimulating the production of red blood cells and reducing the need for blood transfusions. While the use of ESAs has shown efficacy in certain populations, their role in HIV-associated anemia requires careful consideration of individual patient factors and potential risks, such as thrombosis.⁷⁶ Addressing iron deficiency is a critical aspect of anemia management. Innovations in iron supplementation include novel formulations, such as intravenous iron, which can be particularly beneficial in individuals with HIV experiencing challenges in oral iron absorption. Optimizing iron stores contributes to improved erythropoiesis and overall treatment outcomes. The field of regenerative medicine holds promise for revolutionizing anemia management. Stem cell therapies, including hematopoietic stem cell transplantation, offer a potential avenue for restoring normal erythropoiesis in individuals with HIV-associated anemia. While in the early stages of exploration, these innovative approaches showcase the potential for long-term anemia resolution.

The advent of precision medicine allows for a more personalized approach to anemia management. Genetic therapies, including gene editing techniques such as CRISPR-Cas9, hold potential for correcting genetic abnormalities contributing to anemia. Tailoring interventions based on individual genetic profiles may pave the way for targeted and curative treatments. Innovations in ART regimens contribute to improved outcomes in individuals with HIV-associated anemia. Tailoring antiretroviral regimens to minimize hematologic side effects, such as zidovudine-induced anemia, ensures a more favorable balance between HIV control and anemia management.⁷⁵ Recognizing the multifactorial nature of anemia in the context of HIV, combination therapies that address multiple aspects of erythropoiesis and iron metabolism are under exploration. Integrated approaches, combining pharmacologic interventions with nutritional support and psychosocial care, offer a holistic strategy for comprehensive anemia management. Innovations in biomarker identification contribute to a more nuanced understanding of anemia etiology and progression. Utilizing biomarkers to monitor treatment response and guide interventions enhances the precision of anemia management, enabling timely adjustments to optimize outcomes. The integration of telemedicine and remote monitoring technologies facilitates more accessible and patient-centered anemia management. Remote monitoring of hemoglobin levels, medication adherence, and symptomatology allows for timely intervention and personalized adjustments to treatment plans. Innovations in anemia management extend beyond medical interventions to include community engagement and patient empowerment. Educational initiatives, peer support networks, and digital health tools empower individuals with HIV-

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

associated anemia to actively participate in their care, fostering a collaborative and informed approach to management.

Challenges and Considerations in Blood Transfusion

While blood transfusions play a vital role in managing severe anemia, including cases associated with Human Immunodeficiency Virus (HIV), several challenges and considerations must be navigated to ensure the safety and efficacy of this therapeutic intervention. The risk of transfusion-transmitted infections poses a significant concern, especially in individuals with HIV. Rigorous screening for infectious agents, including HIV, hepatitis B and C, and syphilis, is essential to minimize the risk of transmission. Continuous advancements in screening technologies contribute to enhancing the safety profile of blood transfusions.⁷⁷ Blood transfusions can have immunomodulatory effects, influencing the recipient's immune response. In the context of HIV, where immune function is already compromised, understanding the potential impact of transfusions on HIV disease progression and the overall immune system is critical. Balancing the benefits of transfusions with potential immunomodulatory effects requires careful consideration. Ensuring compatibility between donor blood and the recipient is a fundamental consideration in preventing transfusion reactions. In individuals with HIV, additional challenges may arise due to the diversity of HIV strains. Crossmatching protocols and selecting blood products from donors with compatible HIV strains become essential considerations in optimizing transfusion outcomes.

The risk of alloimmunization, where the recipient develops antibodies against donor blood antigens, is a consideration in repeated transfusions. Individuals with HIV may be more prone to alloimmunization due to the chronic inflammatory state associated with the virus. Monitoring for alloimmunization and its potential impact on future transfusions is crucial. Transfusion-related acute lung injury (TRALI) is a rare but severe complication of blood transfusions. In individuals with HIV, the risk of TRALI may be influenced by the underlying inflammatory state. Vigilance in recognizing and managing TRALI is essential for optimizing patient safety. Chronic or repeated blood transfusions can lead to iron overload, presenting a particular concern in individuals with HIV who may already face challenges in iron metabolism. Monitoring and managing iron levels, potentially through chelation therapy, are considerations to prevent complications associated with hemochromatosis. Blood transfusions often involve ethical and cultural considerations, with some individuals refusing transfusions based on personal or religious beliefs. In the context of HIV, addressing these considerations requires open communication, respect for individual autonomy, and alternative approaches to anemia management when necessary. Blood transfusions require significant resources, including screening, crossmatching, and donor blood availability. In resource-limited settings, ensuring access to safe blood products, proper screening protocols, and adherence to safety standards present additional challenges in the effective implementation of blood transfusions.

Patient-Centered Approaches and Quality of Life

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

Recognizing the impact of anemia on the overall well-being of individuals living with Human Immunodeficiency Virus (HIV), adopting patient-centered approaches becomes paramount.⁷⁸ A patient-centered approach begins with a holistic assessment that extends beyond physical symptoms. Understanding the psychosocial aspects of anemia, including its impact on daily functioning, emotional well-being, and overall quality of life, informs a more comprehensive treatment plan. Tailoring treatment plans to the unique needs and preferences of each individual is fundamental. Recognizing that anemia management is not a one-size-fits-all endeavor, healthcare providers collaborate with patients to develop personalized interventions that align with their goals, values, and lifestyle. Open and transparent communication establishes a foundation for shared decision-making. Engaging individuals in discussions about their anemia, treatment options, and potential impacts on their quality of life fosters a collaborative relationship between healthcare providers and patients.

Anemia can have profound psychosocial implications, affecting mood, energy levels, and overall emotional well-being. Incorporating psychosocial support services, including counseling and support groups, provides individuals with a platform to address emotional challenges and enhances their ability to cope with the dual burden of HIV and anemia.⁷⁸ Empowering individuals with knowledge about their condition is a central tenet of patient-centered care. Educational initiatives that provide information about the causes of anemia, available treatment options, and self-management strategies contribute to informed decision-making and improved treatment adherence. Stigma associated with HIV and anemia can exacerbate mental health challenges. Patient-centered care includes strategies to address stigma, reduce discrimination, and support mental health. This may involve integrating mental health professionals into the care team and fostering a stigma-free healthcare environment. Regular monitoring of treatment outcomes, coupled with ongoing assessment of patient goals and preferences, allows for timely adaptations to the treatment plan. Understanding the dynamic nature of anemia and its impact on the patient's life ensures that interventions remain aligned with evolving needs. Empowering individuals to actively participate in their care enhances self-management. This includes strategies for monitoring symptoms, recognizing signs of anemia exacerbation, and engaging in lifestyle modifications or adherence to prescribed interventions to optimize outcomes. Patient-centered care embraces cultural sensitivity, recognizing and respecting diverse beliefs and practices. Understanding cultural perspectives on health, illness, and treatment preferences contributes to a more inclusive and effective approach to anemia management in individuals with HIV. Routine assessments of quality of life, utilizing validated instruments, provide a quantifiable measure of the impact of anemia and its management on the individual. Incorporating quality of life assessments into clinical care guides interventions aimed at improving overall well-being.

Conclusion

The management of anemia in individuals living with Human Immunodeficiency Virus (HIV) requires a multifaceted and patient-centered approach. As we navigate the complexities of this dual burden, it becomes evident that advancements in understanding HIV-related mechanisms of anemia, clinical considerations, blood transfusions, and innovative approaches have significantly

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

influenced the landscape of anemia management. The HIV-related mechanisms contributing to anemia underscore the need for targeted interventions. From direct viral effects on erythropoiesis to the immunomodulatory consequences of chronic inflammation, healthcare providers must consider the intricate interplay between the virus and hematopoiesis when devising treatment plans. Clinical considerations play a pivotal role in guiding the assessment and management of anemia. Accurate diagnosis, severity classification, and identification of contributory factors are essential components of a comprehensive care plan. Balancing the challenges associated with antiretroviral therapy, opportunistic infections, and individual patient characteristics is critical for optimizing outcomes.

Blood transfusions emerge as a cornerstone intervention in the acute management of severe anemia. However, challenges such as transfusion-transmitted infections, immunomodulatory effects, and ethical considerations necessitate a nuanced and patient-centered approach. Understanding the impact of blood transfusions on HIV disease progression and immune function is crucial for ensuring the safety and efficacy of this intervention. Innovative approaches in anemia management, including erythropoiesis-stimulating agents, iron supplementation, and regenerative medicine, offer promising avenues for improving outcomes. The evolving field of precision medicine and genetic therapies holds potential for personalized and curative interventions, reflecting the ongoing commitment to advancing care for individuals with HIV-associated anemia.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

- State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. [https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI: [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanja CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

- Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](#).
18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](#).
 19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
 20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)
 21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
 22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
 23. Obeagu EI, Ameorpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
 24. Obeagu EI, Scott GY, Ameorpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
 25. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
 26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: [DOI: 10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137).
34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

35. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Sтивен PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
38. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
40. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
41. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.researchgate.net/publication/311111111/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY).
42. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
43. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: [10.22192/ijcrps.2019.06.12.004](https://doi.org/10.22192/ijcrps.2019.06.12.004) [links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.researchgate.net/publication/341111111/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
44. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a62edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.researchgate.net/publication/36454a4a62edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

45. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.epjournals.com/links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
46. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
51. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharma Research.* 2014; 391:186-189.
54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Ezemima MC, Okpomesine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
64. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep.* 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30

69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
74. Fujiwara PI, Clevenbergh P, Dlodlo RA. Management of adults living with HIV/AIDS in low-income, high-burden settings, with special reference to persons with tuberculosis [State of the Art Series. HIV infection in low-income, high-burden settings, Edited by JF Murray. Number 5 in the series]. *The International Journal of Tuberculosis and Lung Disease*. 2005;9(9):946-958.
75. Martin R, Esper A, Martin GS. Hematologic Complications. *Non-Pulmonary Complications of Critical Care: A Clinical Guide*. 2014:61-103.
76. Fischer D, Neb H, Choorapoikayil S, Zacharowski K, Meybohm P. Red blood cell transfusion and its alternatives in oncologic surgery—A critical evaluation. *Critical reviews in oncology/hematology*. 2019; 134:1-9.
77. Dodd RY. The risk of transfusion-transmitted infection. *New England journal of medicine*. 1992;327(6):419-421.
78. Wal P, Saed A, Almahtout AM, Ahmed SA. A Multidisciplinary Exploration of Diseases, Treatments, and Impact, From Cancer-Related Anemia to Pandemics and Therapeutics. *Libyan Journal of Medical and Applied Sciences*. 2023:14-30.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30